We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prolactin Stimulates MS Remission

By Biotechdaily staff writers
Posted on 05 Mar 2007
Researchers working with a mouse model of multiple sclerosis (MS) have found that the disease went into remission when the mice became pregnant and that the hormone prolactin could mimic this condition in non-pregnant animals. More...


MS is a chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord or both, interfering with the nerve pathways and causing muscular weakness, loss of coordination, and speech and visual disturbances. Investigators at the University of Calgary (Alberta, Canada) were looking for an explanation at the molecular level as to why MS, a disease that affects about 2.5 million people worldwide, often goes into remission during pregnancy.

They reported in the February 21, 2007, issue of the Journal of Neuroscience that pregnant mice showed an increase in the generation of myelin-forming oligodendrocytes and in the number of myelinated axons in the central nervous system. The pregnant mice had twice as many oligodendrocytes and continued to generate new ones during pregnancy. After giving birth, these mice also had 50% more myelin coating their nerve cells. A significant additional finding was that the hormone prolactin could stimulate remyelination in non-pregnant animals.

"It was thought that during pregnancy, their immune systems no longer destroyed the myelin,” said senior author Dr. Samuel Weiss, professor of neurosciences at the University of Calgary. "But no previous study has tested whether pregnancy actually results in the production of new myelin, which may explain improvement of symptoms.”
Prolactin is a single chain polypeptide of 199 amino acids with a molecular weight of about 24,000 Dda. Its structure is similar to that of growth hormone and placental lactogen. The molecule is folded due to the activity of three disulfide bonds. Prolactin is synthesized and secreted by lactotrope cells in the anterior pituitary gland. It is also produced in other tissues including the breast and the decidua. Pituitary prolactin secretion is regulated by neuroendocrine neurons in the hypothalamus, most importantly by neurosecretory dopamine neurons of the arcuate nucleus, which inhibit prolactin secretion.


Related Links:
University of Calgary

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.